"Mutation" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
| Descriptor ID |
D009154
|
| MeSH Number(s) |
G05.365.590
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Mutation".
Below are MeSH descriptors whose meaning is more specific than "Mutation".
This graph shows the total number of publications written about "Mutation" by people in this website by year, and whether "Mutation" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 5 | 6 |
| 1997 | 3 | 8 | 11 |
| 1998 | 1 | 3 | 4 |
| 1999 | 0 | 11 | 11 |
| 2000 | 3 | 11 | 14 |
| 2001 | 3 | 7 | 10 |
| 2002 | 5 | 9 | 14 |
| 2003 | 2 | 22 | 24 |
| 2004 | 5 | 20 | 25 |
| 2005 | 3 | 19 | 22 |
| 2006 | 6 | 27 | 33 |
| 2007 | 3 | 15 | 18 |
| 2008 | 3 | 15 | 18 |
| 2009 | 5 | 20 | 25 |
| 2010 | 8 | 20 | 28 |
| 2011 | 12 | 19 | 31 |
| 2012 | 7 | 21 | 28 |
| 2013 | 2 | 22 | 24 |
| 2014 | 6 | 17 | 23 |
| 2015 | 6 | 20 | 26 |
| 2016 | 18 | 21 | 39 |
| 2017 | 13 | 31 | 44 |
| 2018 | 4 | 23 | 27 |
| 2019 | 7 | 21 | 28 |
| 2020 | 9 | 29 | 38 |
| 2021 | 12 | 30 | 42 |
| 2022 | 0 | 13 | 13 |
| 2023 | 0 | 10 | 10 |
| 2024 | 3 | 5 | 8 |
| 2025 | 2 | 11 | 13 |
| 2026 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mutation" by people in Profiles.
-
Ubiquitination of Oncogenic Mutant p53 via Attenuation of Ribosome Biogenesis Machinery Effectively Inhibits Pancreatic Tumor Growth. Mol Cancer Ther. 2026 Feb 04; 25(2):257-271.
-
A mechanism for telomere-specific telomere length regulation. Nucleic Acids Res. 2026 Jan 05; 54(1).
-
TRAF7 in signaling and disease: emerging mechanisms and clinical implications. Mol Med. 2025 Dec 11; 32(1):4.
-
Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer. Ann Oncol. 2026 Apr; 37(4):503-520.
-
Impact of SPOP Mutations on Clinical Outcomes in Metastatic Prostate Cancer. JCO Precis Oncol. 2025 Dec; 9:e2500590.
-
Efficacy and safety of BRAF-MEK dual inhibition in BRAF-V600E mutated papillary craniopharyngioma: a systematic review. J Neurooncol. 2025 Oct 30; 176(1):58.
-
Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T. JCO Precis Oncol. 2025 Oct; 9:e2500119.
-
Ziftomenib in Relapsed or Refractory NPM1-Mutated AML. J Clin Oncol. 2025 Nov; 43(31):3381-3390.
-
PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P. JCO Precis Oncol. 2025 Aug; 9:e2500265.
-
The low-fidelity DNA Pol IV accelerates evolution of pathogenicity genes in Pseudomonas aeruginosa. Commun Biol. 2025 Aug 02; 8(1):1148.